Lara D. Veeken · 2014 · 28 citations · 27 references
Veterinary MedicineImmunologyPathobiologyAutoimmunityImmunopathologyInflammationCytokine BiologyEndothelial ActivationEndothelial DysfunctionInflammatory MediatorsInflammatory SignalingSystemic Lupus ErythematosusAutoantibody GenerationCardiovascular InvolvementCytokine-mediated Vascular ResponsesEndothelial DifferentiationEndothelial Progenitor CellsInflammatory Cytokine EffectsInterleukin-10 Mediated ImmunosuppressionLeukocyte-endothelium Interactions
OBJECTIVE: SLE is an autoimmune disease characterized by autoantibody generation, organ damage and an increased risk of cardiovascular disease. Generally considered an anti-inflammatory cytokine, IL-10 is increased in SLE and correlates with poor cardiovascular outcomes in the general population. The aim of this study was to explore the putative role of IL-10 in modulating endothelial function in SLE by examining the effects of this cytokine on endothelial progenitor cell/circulating angiogenic cell (EPC/CAC) differentiation. METHODS: Human and murine control and lupus EPCs/CACs were differentiated into mature endothelial cells (ECs) in the presence or absence of graded concentrations of recombinant IL-10 with or without recombinant IFN-α or a neutralizing antibody to IL-10. IL-10-deficient mice were examined to assess the role of this cytokine in type I IFN-mediated inhibition of EC differentiation and neo-angiogenesis using an in vivo Matrigel plug assay. Serum IL-10 concentrations were measured via ELISA. RESULTS: IL-10 hampers EC differentiation in a dose-dependent manner. In murine EPC cultures, IL-10 is required to observe the inhibitory effects of type I IFNs on EPC function and neo-angiogenesis. In human SLE EPC/CAC cultures, neutralization of IL-10 significantly improved the differentiation of EPCs, and IL-10 enhanced type I IFN-mediated EPC/CAC dysfunction. The presence of IL-10 in serum inversely correlated with EPC/CAC function in SLE but not in control cells. CONCLUSION: IL-10 interferes with endothelial differentiation and may enhance the effects of type I IFN on vascular repair in SLE. IL-10 may be a relevant target for improving cardiovascular risk in SLE.
27
S Manzi, Elaine N. Meilahn, Joan E. Rairie et al. · American Journal of Epidemiology · 1997 · 1.8K citations
Type I Interferon Inhibits Interleukin-1 Production and Inflammasome Activation
Greta Guarda, Marion Braun, Francesco Staehli et al. · Immunity · 2011 · 926 citations · Full text
Protective Role of Interleukin-10 in Atherosclerosis
Ziad Mallat, Sandrine Besnard, Micheline Duriez et al. · Circulation Research · 1999 · 829 citations · Full text